Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS636 in relapsed or refractory primary mediastinal large B-cell lymphoma
CTR20210265Phase 2Suspended
- Sponsor
- Zhejiang Hisun Pharmaceutical Co., Ltd.
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of sudubrilimab in primary mediastinal large B-cell lymphoma (PMBCL), sponsored by Zhejiang Hisun Pharmaceutical Co., Ltd.. Started Nov 2021; status: suspended.
02
Drugs
sudubrilimab
03
Conditions
primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on CTR20210265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210265.